替考拉宁用于耐甲氧西林金黄色葡萄球菌感染心内膜炎的现状和启示

doi:10.3969/j.issn.1671-7171.2019.04.033

摘要
图/表
参考文献
相关文章 (15)

[1] 齐慧敏,马序竹,张朴,等.持续不卧床腹膜透析患者静注替考拉宁的药代动力学[J].中国临床药理学杂志,2008,24(3):212-215.
[2] 李朋梅,陈文倩,王晓雪,等.替考拉宁的药动学影响因素及治疗药物监测研究进展[J].中国医院用药评价与分析,2016,16(7):865-868.
[3] Ueda T,Takesue Y,Nakajima K,et al. High-dose regimen to achieve novel target trough concentration in teicoplanin[J].J Infect Chemother,2014, 20(1):43-47.
[4] 孙芳. 应用蒙特卡洛模拟法优化利奈唑胺、替考拉宁和万古霉素在ICU患者治疗MRSA感染的给药方案[J].中国抗生素杂志,2016,41(10):796-800.
[5] Habib G , Lancellotti P , Antunes MJ,et al. 2015 ESC Guidelines for the management of infective endocarditis[J].Heart,2016, 102(13):992-994.
[6] Baddour LM , Wilson WR , Bayer AS , et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association[J].Circulation,2015,132(15):1435-1486.
[7] 中华医学会心血管病学分会.成人感染性心内膜炎预防、诊断和治疗专家共识[J].中华心血管病杂志,2014,42(10):806-816.
[8] Saravu K, Mukhopadhyay C, Satyanarayanan V, et al. Successful treatment of right-sided native valve methicillin-resistant staphylococcus aureus endocarditis and septicaemia with teicoplanin and rifampicin: a case report[J].Scand J Infect Dis,2012,44(7):544-547.
[9] 王俊锋,郭学光,方向群等.利奈唑胺和替考拉宁序贯治疗老年革兰阳性球菌重症肺炎的临床观察[J].中华保健医学杂志,2013,15(1):3-5.
[10] 李宁.替考拉宁与万古霉素治疗MRSA下呼吸道感染的临床疗效和安全性分析[J].中国微生态学杂志,2015,27(11):1325-1327.
[11] 林婷婷, 陈晨云, 陈艳锦. 替考拉宁与万古霉素治疗MRSA肺炎效果及对细菌清除率的影响分析[J].海峡药学,2018,30(5):113-116.
[12] Boumis E,Gesu G,Menichetti F.et al.Consensus document on controversial issues in the diagnosis and treatment of bloodstream infections and endocarditis[J].Int Infect Dis,2010,14(suppl):S23-S28.[13] Lee CH, Tsai CY , Li CC,et al. Teicoplanin therapy for MRSA bacteraemia: a retrospective study emphasizing the importance of maintenance dosing in improving clinical outcomes[J].J Antimicrob Chemother,2015, 70(1):257-263.
[14] 郭文杰,罗鹏,荆许恩,等.抗菌肽对耐甲氧西林金黄色葡萄球菌的抗菌机制研究进展[J].中国药房,2017,28(23):3302-3305.
[15] 邓少嫦,罗银珠,李航,等.耐甲氧西林金黄色葡萄球菌系统性感染小鼠模型的制备[J].中国实验动物学报,2016,24(6):596-600.
[16] 刘蓓,王哲,李坤,等.大剂量替考拉宁治疗耐甲氧西林金黄色葡萄球菌感染呼吸机相关性肺炎的疗效观察[J].河北医药,2015,37(2):218-220.
[17] 祖育娜,张华,周丽娟,等.不同剂量替考拉宁治疗老年重症革兰阳性菌感染患者的治疗药物浓度监测与疗效评估[J].中华医院感染学杂志, 2016,26(23):5379-5381.
[18] 周丽娟,郑惠,刘嘉,等.不同负荷剂量替考拉宁治疗 MRSA 感染肺炎患者的临床疗效和安全性评价[J].中华医院感染学杂志,2017,27(2):313-316.
[19] 杨睿,鲁新华,张国俊.不同起始负荷剂量替考拉宁治疗革兰阳性菌下呼吸道感染的疗效与安全性评价[J].中华医院感染学杂志,2015,25(20):4673-4676.
[20] Nakano T , Nakamura Y , Togawa A , et al. Necessity of personalized initial loading dose calculation of teicoplanin by clinical pharmacistmdash;examination of the utility of using systemic inflammatory response syndrome score mdash[J].Yakugaku Zasshi,2014,134(12):1367-1373.
[21] Davey PG, Williams AH. Teicoplanin monotherapy of serious infections caused by Gram-positive bacteria: a re-evaluation of patients with endocarditis or Staphylococcus aureus bacteraemia from a European open trial[J].J Antimicrob Chemother,1991,27(suppl_B):43-50.
[22] Sato Y, Hiramatsu K, Suzuki Y, et al. Optimal trough concentration of teicoplanin in febrile neutropenic patients with hematological malignancy[J].Chemotherapy,2018,63(1):29-34.
[23] Yoshida S, Suzuki A, Ohmori T, et al.A simplified chart for determining the initial loading dose of teicoplanin in critically ill patients[J].Pharmazie,2017,72(1):53-57.